Doxorubicin Hydrochloride liposome Injection

SECTION 2: Hazards identification

COMPONENT CAS# FORMULA PERCENT Doxorubicin Hydrochloride 25316-40-9 C27H29NO11-HCl 0.2 % Liposomal carrier* not applicable 99.8 %

Contains

N-(carbamoyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3- phosphoethanolamine sodium salt (MPEG-DSPE), fully hydrogenated soy phosphatidylcholine (HSPC), cholesterol, ammonium sulphate, histidine, sucrose and hydrochloric acid and/or sodium hydroxide for pH control. SECTION 3. HAZARDS INFORMATION WARNING STATEMENT CAUTION: Contains Doxorubicin Hydrochloride an antineoplastic agent used in chemotherapy. Doxorubicin Hydrochloride is a known carcinogen in animals and a probable carcinogen in humans. This drug is intended for human pharmaceutical use by intravenous infusion as prescribed by a physician. SECTION 3. HAZARDS INFORMATION (CONTINUED) Precautionary statement: Irritant :Irritating to eyes, skin and mucosa Potential route of exposure :Skin, eyes, ingestion, inhalation, accidental injection. Systemic Acute: Due to the nature of the use (intravenous infusion) of this drug no oral or inhalation toxicity data exists. Chronic: Due to the nature of the use (intravenous infusion) of this drug no oral or inhalation toxicity data exists. May cause reproductive and developmental toxicity. May cause carcinogenicity and mutagenicity. No permissible exposure limits have been set.